Interstitial Pneumonitis Related to Rituximab Therapy
- 26 June 2003
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (26) , 2690-2691
- https://doi.org/10.1056/nejm200306263482619
Abstract
Rituximab targets CD20+ B cells. It is used increasingly for the treatment of B-cell non-Hodgkin's lymphoma, alone or in combination with cytotoxic agents.1,2 We report two patients with non-Hodgkin's lymphoma in whom interstitial pneumonitis developed after rituximab therapy.Keywords
This publication has 6 references indexed in Scilit:
- Drug-induced Lung Disease: High-resolution CT and Histological FindingsClinical Radiology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Drug-induced lung injurySeminars in Roentgenology, 2002
- Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapyBone Marrow Transplantation, 2001
- Tumor necrosis factor α release is a major biological event associated with rituximab treatmentThe Hematology Journal, 2001
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphomaBlood, 2000